{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:04:56Z","timestamp":1784120696756,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12381-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:13:29Z","timestamp":1784117609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigallocatechin gallate enhances panobinostat-induced cytotoxicity through HDAC modulation in colorectal cancer cells"],"prefix":"10.1007","volume":"53","author":[{"given":"Mai Kamal","family":"Khader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-1879","authenticated-orcid":false,"given":"Manal A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Y.","family":"Al-Kabariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"2","key":"12381_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338\u2013344.","journal-title":"Gut"},{"issue":"9","key":"12381_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jama.2025.11473","volume":"334","author":"CC Murphy","year":"2025","unstructured":"Murphy CC, Sedani AE, Balasubramanian BA (2025) Younger adults, earlier screening-what we are learning about colorectal cancer and what comes next. JAMA 334(9):773\u2013775 Epub 20250804. https:\/\/doi.org\/10.1001\/jama.2025.11473","journal-title":"JAMA"},{"key":"12381_CR3","doi-asserted-by":"publisher","unstructured":"Abukhalil MH, Al-Alami Z, Alfwuaires MA, Imran MR, Aladaileh SH, Althunibat OY (2025) Taxifolin protects against 5-fluorouracil-induced cardiotoxicity in mice through mitigating oxidative stress, inflammation, and apoptosis: Possible involvement of Sirt1\/Nrf2\/HO-1 signaling. Cardiovasc Toxicol 25(3):455\u2009\u2013\u200970.https:\/\/doi.org\/10.1007\/s12012-025-09962-w","DOI":"10.1007\/s12012-025-09962-w"},{"issue":"13","key":"12381_CR4","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.3390\/ijms25137470","volume":"25","author":"M Barathan","year":"2024","unstructured":"Barathan M, Zulpa AK, Ng SL, Lokanathan Y, Ng MH, Law JX (2024) Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles. Int J Mol Sci 25(13):7470. https:\/\/doi.org\/10.3390\/ijms25137470","journal-title":"Int J Mol Sci"},{"issue":"10","key":"12381_CR5","doi-asserted-by":"publisher","first-page":"e0334427","DOI":"10.1371\/journal.pone.0334427","volume":"20","author":"DR Abu Alsamen","year":"2025","unstructured":"Abu Alsamen DR, Zakaraya ZZ, Abed A, Alsa\u2019d AA, Alnajdawi MR (2025) Synergistic anticancer effects of ABT-199 and Vorinostat encapsulated in PLGA nanoparticles: Formulation, characterization, and antiproliferative effects against colorectal cancer cells. PLoS ONE 20(10):e0334427 Epub 20251010. https:\/\/doi.org\/10.1371\/journal.pone.0334427","journal-title":"PLoS ONE"},{"key":"12381_CR6","doi-asserted-by":"publisher","first-page":"1576781","DOI":"10.3389\/fonc.2025.1576781","volume":"15","author":"J Tian","year":"2025","unstructured":"Tian J, Han M, Song F, Liu Y, Shen Y, Zhong J (2025) Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation. Front Oncol 15:1576781.","journal-title":"Front Oncol"},{"issue":"3","key":"12381_CR7","doi-asserted-by":"publisher","first-page":"e70127","DOI":"10.1002\/mco2.70127","volume":"6","author":"J Li","year":"2025","unstructured":"Li J, Pan J, Wang L, Ji G, Dang Y (2025) Colorectal cancer: pathogenesis and targeted therapy. MedComm 6(3):e70127.","journal-title":"MedComm"},{"issue":"2","key":"12381_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/or.2011.1312","volume":"26","author":"J Higashijima","year":"2011","unstructured":"Higashijima J, Kurita N, Miyatani T, Yoshikawa K, Morimoto S, Nishioka M et al (2011) Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol Rep 26(2):343\u2013348. https:\/\/doi.org\/10.3892\/or.2011.1312","journal-title":"Oncol Rep"},{"issue":"4","key":"12381_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1874467212666190313154531","volume":"12","author":"SA Najem","year":"2019","unstructured":"Najem SA, Khawaja G, Hodroj MH, Rizk S (2019) Synergistic effect of epigenetic inhibitors decitabine and suberoylanilide hydroxamic acid on colorectal cancer in vitro. Curr Mol Pharmacol 12(4):281\u2013300.","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"12381_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/RPS.RPS_59_24","volume":"20","author":"NA Alqalalwah","year":"2025","unstructured":"Alqalalwah NA, Abbas MM, Abbas MA, Obeidat R, El-Rayyes R (2025) Genistein potentiated the cytotoxic effect of entinostat in colorectal cancer cell lines. Res Pharm Sci 20(3):408\u2013415.","journal-title":"Res Pharm Sci"},{"key":"12381_CR11","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.adcanc.2025.100136","volume":"14","author":"W Jin","year":"2025","unstructured":"Jin W, Wang J-j, Feng Y-f, Chen B, Hu Z-h (2025) HDAC3-mediated deacetylation of p21 stabilizes protein levels and promotes 5-FU resistance in colorectal cancer cells. Adv Cancer Biology-Metastasis 14:100136.","journal-title":"Adv Cancer Biology-Metastasis"},{"issue":"Spec Feature","key":"12381_CR12","first-page":"84","volume":"9","author":"Raedler","year":"2016","unstructured":"Raedler LA (2016) Farydak (Panobinostat): First HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 9(Spec Feature):84\u201387.","journal-title":"Am Health Drug Benefits"},{"issue":"3","key":"12381_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/bjh.12384","volume":"162","author":"DJ DeAngelo","year":"2013","unstructured":"DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M et al (2013) Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 162(3):326\u2013335. https:\/\/doi.org\/10.1111\/bjh.12384","journal-title":"Br J Haematol"},{"issue":"4suppl","key":"12381_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1200\/jco.2012.30.4_suppl.582","volume":"30","author":"PJ Gold","year":"2012","unstructured":"Gold PJ, Smith DA, Iriarte D, Boatman B, Kaplan HG (2012) Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC). J Clin Oncol 30(4suppl):582.","journal-title":"J Clin Oncol"},{"key":"12381_CR15","doi-asserted-by":"publisher","unstructured":"Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W et al (2015) Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett 356(2 Pt B):656\u2009\u2013\u200968. https:\/\/doi.org\/10.1016\/j.canlet.2014.10.015","DOI":"10.1016\/j.canlet.2014.10.015"},{"issue":"9","key":"12381_CR16","doi-asserted-by":"publisher","first-page":"e76662","DOI":"10.1371\/journal.pone.0076662","volume":"8","author":"G Wang","year":"2013","unstructured":"Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW et al (2013) Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS ONE 8(9):e76662. https:\/\/doi.org\/10.1371\/journal.pone.0076662","journal-title":"PLoS ONE"},{"key":"12381_CR17","doi-asserted-by":"publisher","unstructured":"Smith KH, Trovillion EM, Sholler C, Gandra D, McKinney KQ, Mulama D et al (2024) Panobinostat synergizes with chemotherapeutic agents and improves efficacy of standard-of-care chemotherapy combinations in ewing sarcoma cells. Cancers 16(21). https:\/\/doi.org\/10.3390\/cancers16213565","DOI":"10.3390\/cancers16213565"},{"issue":"3","key":"12381_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4196\/kjpp.24.274","volume":"29","author":"H Zhao","year":"2025","unstructured":"Zhao H, Wu Y, Kim SM (2025) Enhancing doxorubicin\u2019s anticancer impact in colorectal cancer by targeting the Akt\/Gsk3beta\/mTOR-SREBP1 signaling axis with an HDAC inhibitor. Korean J Physiol Pharmacol 29(3):321\u2013335. https:\/\/doi.org\/10.4196\/kjpp.24.274","journal-title":"Korean J Physiol Pharmacol"},{"key":"12381_CR19","unstructured":"Yaseen AA (2011) The natural polyphenol resveratrol potentiates the lethality of hdac inhibitors in acute myelogenous leukemia cells through multiple mechanisms."},{"key":"12381_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.17179\/excli2020-3181","volume":"20","author":"MA Franco-Molina","year":"2021","unstructured":"Franco-Molina MA, Santana-Krimskaya SE, Madrigal-de-Leon LM, Coronado-Cerda EE, Zarate-Trivino DG, Hernandez-Martinez SP et al (2021) Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and Lophophora williamsii extract against C6 glioma cells. EXCLI J 20:614\u2013624. https:\/\/doi.org\/10.17179\/excli2020-3181","journal-title":"EXCLI J"},{"issue":"5","key":"12381_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3892\/ol.2013.1533","volume":"6","author":"SY Park","year":"2013","unstructured":"Park SY, Jung CH, Song B, Park OJ, Kim YM (2013) Pro\u2013apoptotic and migration\u2013suppressing potential of EGCG, and the involvement of AMPK in the p53\u2013mediated modulation of VEGF and MMP\u20139 expression. Oncol Lett 6(5):1346\u20131350.","journal-title":"Oncol Lett"},{"issue":"1","key":"12381_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jphs.2015.04.003","volume":"128","author":"F Hu","year":"2015","unstructured":"Hu F, Wei F, Wang Y, Wu B, Fang Y, Xiong B (2015) EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. J Pharmacol Sci 128(1):27\u201334.","journal-title":"J Pharmacol Sci"},{"issue":"9","key":"12381_CR23","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.21873\/anticanres.15240","volume":"41","author":"MW Shin","year":"2021","unstructured":"Shin MW, Kim SL, Yang HC, Yim SK, Seo SY, Lee ST et al (2021) The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells. Anticancer Res 41(9):4353\u20134364. https:\/\/doi.org\/10.21873\/anticanres.15240","journal-title":"Anticancer Res"},{"issue":"4","key":"12381_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10637-012-9914-7","volume":"31","author":"PM Wilson","year":"2013","unstructured":"Wilson PM, LaBonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz H-J et al (2013) Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Investig New Drugs 31(4):845\u2013857. https:\/\/doi.org\/10.1007\/s10637-012-9914-7","journal-title":"Investig New Drugs"},{"issue":"10","key":"12381_CR25","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-10-2430","volume":"71","author":"MJ LaBonte","year":"2011","unstructured":"LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A et al (2011) The dual EGFR\/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 71(10):3635\u20133648. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2430","journal-title":"Cancer Res"},{"issue":"1","key":"12381_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.nucmedbio.2015.10.003","volume":"43","author":"S Maschauer","year":"2016","unstructured":"Maschauer S, Gahr S, Gandesiri M, Tripal P, Schneider-Stock R, Kuwert T et al (2016) In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers. Nucl Med Biol 43(1):27\u201334. https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.10.003","journal-title":"Nucl Med Biol"},{"issue":"5","key":"12381_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3892\/ol.2013.1533","volume":"6","author":"SY Park","year":"2013","unstructured":"Park SY, Jung CH, Song B, Park OJ, Kim YM (2013) Pro-apoptotic and migration-suppressing potential of EGCG, and the involvement of AMPK in the p53-mediated modulation of VEGF and MMP-9 expression. Oncol Lett 6(5):1346\u20131350.","journal-title":"Oncol Lett"},{"key":"12381_CR28","doi-asserted-by":"publisher","unstructured":"Lee NR, Kim DY, Jin H, Meng R, Chae OH, Kim SH et al (2021) Inactivation of the Akt\/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells. Int J Mol Sci 22(11). https:\/\/doi.org\/10.3390\/ijms22115955","DOI":"10.3390\/ijms22115955"},{"issue":"3","key":"12381_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-014-2979-6","volume":"145","author":"LV Rhodes","year":"2014","unstructured":"Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V et al (2014) Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 145(3):593\u2013604","journal-title":"Breast Cancer Res Treat"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12381-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:13:34Z","timestamp":1784117614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12381-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12381"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12381-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Declaration of AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1167"}}